NCCN guidelines update: Breast cancer

William Gradishar*, Kilian E. Salerno

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


The updates to management of early invasive breast cancer in 2016 are minor but have important treatment implications for patients. The NCCN Guidelines Panel for Breast Cancer has added endocrine therapy to its recommendations for the neoadjuvant treatment of patients with ER-rich tumors. For women who are premenopausal at diagnosis, the NCCN Guidelines suggest tamoxifen for 5 years, with or without ovarian suppression, or an aromatase inhibitor for 5 years combined with ovarian suppression or ablation. For HER2-positive patients, neoadjuvant pertuzumab is acceptable, and in advanced estrogen receptor-positive disease, palbociclib can be given with endocrine therapy. Hypofractionation is now the preferred approach for whole-breast irradiation after breast-conserving therapy. Regional nodal irradiation should be strongly considered for women with 1 to 3 positive lymph nodes and is indicated for those with 4 or more positive nodes.

Original languageEnglish (US)
Pages (from-to)641-644
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
StatePublished - May 1 2016

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'NCCN guidelines update: Breast cancer'. Together they form a unique fingerprint.

Cite this